JP2004534741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534741A5 JP2004534741A5 JP2002576291A JP2002576291A JP2004534741A5 JP 2004534741 A5 JP2004534741 A5 JP 2004534741A5 JP 2002576291 A JP2002576291 A JP 2002576291A JP 2002576291 A JP2002576291 A JP 2002576291A JP 2004534741 A5 JP2004534741 A5 JP 2004534741A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- fragment
- cancer
- antibody
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 4
- 230000001472 cytotoxic effect Effects 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 claims 2
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR3958 | 2001-03-26 | ||
| AUPR3958A AUPR395801A0 (en) | 2001-03-26 | 2001-03-26 | Antibodies against cancer |
| PCT/AU2002/000362 WO2002077033A1 (en) | 2001-03-26 | 2002-03-26 | Antibodies against cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008188842A Division JP2009024014A (ja) | 2001-03-26 | 2008-07-22 | 癌に対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534741A JP2004534741A (ja) | 2004-11-18 |
| JP2004534741A5 true JP2004534741A5 (cg-RX-API-DMAC7.html) | 2005-12-22 |
| JP4854912B2 JP4854912B2 (ja) | 2012-01-18 |
Family
ID=3827964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002576291A Expired - Fee Related JP4854912B2 (ja) | 2001-03-26 | 2002-03-26 | 癌に対する抗体 |
| JP2008188842A Pending JP2009024014A (ja) | 2001-03-26 | 2008-07-22 | 癌に対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008188842A Pending JP2009024014A (ja) | 2001-03-26 | 2008-07-22 | 癌に対する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7318924B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1383801A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4854912B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100909290B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN100457781C (cg-RX-API-DMAC7.html) |
| AU (3) | AUPR395801A0 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2442318A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ528624A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002077033A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| CA2443840C (en) | 2001-04-26 | 2010-10-26 | Biogen, Inc. | Cripto blocking antibodies and uses thereof |
| WO2004037990A2 (en) * | 2002-10-23 | 2004-05-06 | Exelixis, Inc. | MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE |
| EP1624073A4 (en) * | 2003-04-03 | 2006-05-17 | Oncorex Inc | DRUG |
| AU2004252170B2 (en) * | 2003-06-27 | 2011-01-27 | Biogen Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| EP2135952A3 (en) | 2003-09-15 | 2010-09-29 | Research Development Foundation | Cripto antagonism of activin and TGF-beta signaling |
| CA2542332C (en) | 2003-10-16 | 2013-03-12 | Stephen John Ralph | Immunomodulating compositions and uses therefor |
| KR20070100346A (ko) * | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | 크립토 결합 분자 |
| US7939056B2 (en) * | 2005-11-14 | 2011-05-10 | The Brigham And Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| CN101970001A (zh) * | 2007-06-01 | 2011-02-09 | 比奥根艾迪克Ma公司 | Cripto结合分子 |
| EP3766517B1 (en) | 2008-06-20 | 2022-11-02 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| KR100973029B1 (ko) * | 2008-10-07 | 2010-08-11 | 박지운 | 알루미늄 합금 가로등 등주 |
| WO2010054328A2 (en) * | 2008-11-07 | 2010-05-14 | Research Development Foundation | Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling |
| JP5990752B2 (ja) * | 2011-01-31 | 2016-09-14 | オリンパス株式会社 | 抗体療法の効果増強剤 |
| CN103826661B (zh) | 2011-04-21 | 2019-03-05 | 西雅图基因公司 | 新的结合剂-药物缀合物(adc)及其用途 |
| JP6721507B2 (ja) | 2013-12-23 | 2020-07-15 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ） |
| KR102739664B1 (ko) * | 2015-04-20 | 2024-12-05 | 미노믹 인터내셔널 리미티드 | 치료용 항체 및 이의 용도 |
| SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| HK1246717A1 (zh) | 2015-06-23 | 2018-09-14 | Bayer Pharma Aktiengesellschaft | Ksp抑制剂的靶向缀合物 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| MX2018011627A (es) | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. |
| EP3471776B1 (en) | 2016-06-15 | 2022-05-04 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies |
| KR102583006B1 (ko) | 2016-12-21 | 2023-09-27 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
| KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| CN109744199A (zh) * | 2017-11-08 | 2019-05-14 | 南京艾莫瑞生物科技有限公司 | 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用 |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5171665A (en) | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
| US5256643A (en) * | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| US5264557A (en) | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| KR20000015893A (ko) | 1996-05-22 | 2000-03-15 | 댄 마이클 | 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도 |
| IL125608A0 (en) * | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| AU766256B2 (en) | 1999-03-11 | 2003-10-09 | Ardenia Investments Ltd. | New compounds for the treatment of cancer |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| JP2004524810A (ja) | 2000-09-18 | 2004-08-19 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ変異体およびその使用 |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| CA2443840C (en) | 2001-04-26 | 2010-10-26 | Biogen, Inc. | Cripto blocking antibodies and uses thereof |
-
2001
- 2001-03-26 AU AUPR3958A patent/AUPR395801A0/en not_active Abandoned
-
2002
- 2002-03-26 US US10/470,013 patent/US7318924B2/en not_active Expired - Fee Related
- 2002-03-26 WO PCT/AU2002/000362 patent/WO2002077033A1/en not_active Ceased
- 2002-03-26 AU AU2002240719A patent/AU2002240719B2/en not_active Ceased
- 2002-03-26 NZ NZ528624A patent/NZ528624A/xx not_active IP Right Cessation
- 2002-03-26 JP JP2002576291A patent/JP4854912B2/ja not_active Expired - Fee Related
- 2002-03-26 CN CNB028073177A patent/CN100457781C/zh not_active Expired - Fee Related
- 2002-03-26 CA CA002442318A patent/CA2442318A1/en not_active Abandoned
- 2002-03-26 EP EP02706533A patent/EP1383801A4/en not_active Withdrawn
- 2002-03-26 CN CNA2008101103851A patent/CN101310770A/zh active Pending
-
2003
- 2003-09-26 KR KR1020037012528A patent/KR100909290B1/ko not_active Expired - Fee Related
-
2007
- 2007-04-11 AU AU2007201587A patent/AU2007201587A1/en not_active Abandoned
-
2008
- 2008-07-22 JP JP2008188842A patent/JP2009024014A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534741A5 (cg-RX-API-DMAC7.html) | ||
| Pinto et al. | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) | |
| Singh et al. | Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer | |
| AU2019396895B2 (en) | Combination of antibody-drug conjugate with PARP inhibitor | |
| JP2008531576A5 (cg-RX-API-DMAC7.html) | ||
| HRP20151257T1 (hr) | Monoklonska protutijela na klaudin-18 za lijeäśenje karcinoma | |
| Park et al. | A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma | |
| NZ528624A (en) | Antibodies against cancer | |
| JP2009505676A5 (cg-RX-API-DMAC7.html) | ||
| JP2018534933A5 (cg-RX-API-DMAC7.html) | ||
| RU2005132788A (ru) | Способ лечения рака у человека (варианты), применяемая в способе форма (варианты) и применение антитела (варианты) | |
| SI2719708T1 (en) | Material and methods for treating or preventing HER-3-related diseases | |
| Aoki et al. | Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective | |
| JP2010535713A5 (cg-RX-API-DMAC7.html) | ||
| RU2007101378A (ru) | Терапия злокачественной опухоли, резистентной к препаратам на основе платины | |
| JP2008503476A5 (cg-RX-API-DMAC7.html) | ||
| HRP20150143T1 (hr) | Imunokonjugati koji ciljaju na cd138 i njihova upotreba | |
| JP2007513073A5 (cg-RX-API-DMAC7.html) | ||
| JP2015508280A5 (cg-RX-API-DMAC7.html) | ||
| JP2011512332A5 (cg-RX-API-DMAC7.html) | ||
| HU231064B1 (hu) | Anti-ErbB2 antitestek adagolási sémái és alkalmazásuk rákos betegségek kezelésére | |
| ME02296B (me) | Postupak za liječenje kancera dll4 antagonistom i hemoterapijskim agensom | |
| JP2018512402A5 (cg-RX-API-DMAC7.html) | ||
| Lu et al. | Exploring the therapeutic potential of ADC combination for triple-negative breast cancer | |
| JPWO2022270524A5 (cg-RX-API-DMAC7.html) |